
June 2018 (Vol. 39, No. 06)


Optimal management of psoriasis symptoms falls short for about three in 10 patients with moderate plaque psoriasis and for one in five with severe psoriasis, a recent study shows.

Immune responses to the latest shingles vaccine (Shingrix) last for at least three years following vaccination. The robust immune responses develop and persist in all age groups, according to a recent study in The Journal of Infectious Diseases.

Study shows no significant difference in herpes zoster risk between psoriasis patients receiving systemic therapy and those not receiving systemic therapy.
Advertisement
Advertisement
Trending on Dermatology Times
1
JAK Inhibitors Show Comparable Safety to TNF Antagonists
2
First-in-Class Topical GT20029 Demonstrates Promising Phase 2 Efficacy and Tolerability for AGA
3
Considering Biologics and Shared Decision-Making in Moderate to Severe Plaque Psoriasis: Part 2
4
"PDE4 Inhibitor-Responsive Dermatoses": A Modern Framework for Managing Inflammatory Skin Conditions
5
